CYP19A1 and breast cancer: Phase III breast cancer chemoprevention trials have now demonstrated the efficacy of selective estrogen receptor (ER) modulators (SERMs) (e.g., tamoxifen and raloxifene) and aromatase inhibitors in reducing the incidence of breast cancer.